Dr. Kaelin is a world-renowned Nobel Laureate, scientist, academician, and physician who provides valuable leadership to the board s oversight of Lilly s discovery and development programs. With decades of preeminent medical research and discovery experience, particularly within oncology, Dr. Kaelin offers a valuable perspective and resource to the board and management in pharmaceutical research and discovery in key therapeutic areas. Dr. Kaelin has extensive experience as a professor and mentor to medical professionals who are key constituents for Lilly s business and workforce. As an investigator at Howard Hughes Medical Institute, Dr. Kaelin has a deep understanding of the challenges, perspectives, and opportunities for medical researchers. Dr. Kaelin also brings commercialization experience to the board through his work with venture capital funds and biotechnology companies. Age: 68 Director Since: 2012 Board Committees: Directors and Corporate Governance Science and Technology (Chair) Other Public Boards: IQVIA Holdings Inc. Recent Prior Public Boards: None Key Skills: CAREER HIGHLIGHTS Harvard Medical School Sidney Farber Professor of Medicine (2018 - present) Professor of Medicine (2002 - 2018) Dana-Farber Cancer Institute Professor (2002 - present) Howard Hughes Medical Institute Investigator (2002 - present) Assistant Investigator (1998 - 2002) OTHER HIGHLIGHTS Recipient of numerous prizes and honors, including: Nobel Prize in Physiology or Medicine Albert Lasker Basic Medical Research Award Canada Gairdner International Award Wiley Prize in Biomedical Sciences from the Rockefeller University Paul Marks Prize for Cancer Research from the Memorial Sloan Kettering Cancer Center Member, National Academy of Medicine; National Academy of Sciences; American College of Physicians; Association of American Physicians; American Society of Clinical Investigation; American Academy of Arts and Sciences; American Philosophical Society